发布时间：2025-03-20 15:14
Galderma will present new data from across its portfolio, including findings from the RELAX and EXPRESSION studies on Relfydess (RelabotulinumtoxinA) highlighting its rapid onset of action as early as day one and sustained high patient satisfaction beyond six months1,2
New in vivo data on Sculptra (PLLA-SCA), the first proven regenerative biostimulator, will be presented, showing its lower inflammatory response compared to PLLA-GA, which can significantly impact local tissue response and product degradation and therefore may impact the duration of clinical effect3-12
Additionally, results from the first-of-its-kind and largest survey on facial changes associated with medication-driven weight loss will be presented showing many patients would consider aesthetic treatments to address these changes, with biostimulators and dermal fillers the most frequently considered13
Galderma will host a symposium exploring how aesthetic treatments can address fa
=*=*=*=*=*=
当前为第1/22页
下一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页